Sucampo Pharmaceuticals agrees to US$2.1bn takeover by Mallinckrodt

Under the terms of the deal, Mallinckrodt will pay US$18 for each Sucampo share, which is 5.9% above Friday's closing price
Biopharma
It said the deal will add at least 30 US cents a share to Mallinckrodt’s adjusted earnings in 2018

Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) saw its shares jump in post-holiday trading after the biopharmaceutical company agreed to a US$2.1bn takeover by Mallinckrodt Pharmaceuticals Limited (NYSE:MKN).

Under the terms of the deal, Mallinckrodt will pay US$18 for each Sucampo share, which is 5.9% above Friday's closing price, and would give Sucampo a total market value of about US$839.5mln.

Mallinckrodt expects to fund the deal, which is forecast to close in the first quarter of 2018, with debt and cash on hand.

It said the deal will add at least 30 US cents a share to Mallinckrodt’s adjusted earnings in 2018.

In afternoon trading, Sucampo shares were 6.2% higher at US$18.05, while Mallinckrodt shares were up 1% at US$23.55.

-- Updates share prices --

View full SCMP profile View Profile

Sucampo Pharmaceuticals Timeline

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © personabelovo.ru, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.